Weill Cornell Medicine has received more than $635,000 in first-year funding for a two-year grant worth up to $1.24 million from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, to study a new approach for delivering an experimental non-opioid pain medication, called